Compare Monster Beverage Corp (MNST) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Spyre Therapeutics Inc. Common Stock — how do they compare? Monster Beverage Corp trades at $44.5 (market cap $84.85B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Monster Beverage Corp is far larger — about 11.3× Spyre Therapeutics Inc. Common Stock's market cap, and Monster Beverage Corp is more actively traded (7,847,331 versus 1,441,031). Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| MNST | SYRE | |
|---|---|---|
Market Cap | $84.85B | $7.52B |
Volume | 7,847,331 | 1,441,031 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $108.92 |
52-Week Low | $33.16 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $83.14B | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $44.22, up 1.05% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust fundamentals including 55.55% gross margin and 23.08% net margin. Recent news highlights international growth, a debt-free balance sheet, and a 1:2 stock split effective August 2026.
Outlook remains positive with analyst consensus target of $98.22 implying significant upside, supported by international expansion and high profitability. Key risks include valuation multiples above industry averages and regulatory challenges in markets like India. The stock's growth trajectory is solid, but investors should weigh rich valuations against execution risks.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
